Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests on the market and in development for colorectal, lung, and prostate cancer aim at aiding in an earlier and more accurate diagnosis of these diseases, thereby potentially increasing the patient's chances of survival. For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. *

	Start	1998-01-01 established
	Group	Epigenomics (Group)
	Predecessor	Epigenomics GmbH
	Industry	molecular diagnostics
	Industry 2	pharmacogenomics/pharmacogenetics
	Person	Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
	Person 2	Staub, Uwe (Epimune 201904– Managing Director before Epigenomics + Qiagen + Digene + Abbott Diagnostics)

	Region	Berlin
	Country	Germany
	Street	5 Geneststr.
	City	10829 Berlin
	Tel	+49-30-24345-0
		Address record changed: 2022-09-17

Basic data	Employees	B: 11 to 50 (2022-12-31)
	Currency	EUR
	Annual sales	485,000 (revenue, consolidated (2022) 2022-12-31)
	Profit	-12,024,000 (2022-12-31)
	Cash	10,126,000 (2022-12-31)

		* Document for »About Section«:

		Record changed: 2023-12-30